Recent Posts
- Ukraine recovery should be based on development of territorial communities, innovations, involvement of professional domestic community – results of ESUR forum 29.06.2023
- Ukraine repatriates five more seriously wounded Russian POWs 10.04.2023
- Rada intends to include history of Ukraine, foreign language in final certification for general secondary education 10.04.2023
- Rada terminates protocol on joint anti-terrorist measures in CIS territories for Ukraine 10.04.2023
- 100 Ukrainians, incl defenders of Mariupol, returned according to swap procedure – Yermak 10.04.2023
Latvian pharmaceutical concern Olainfarm increases sales in Ukraine by 24% in H1 2021
KYIV. Aug 30 (Interfax-Ukraine) – In January-June 2021, the Latvian pharmaceutical concern Olainfarm increased sales of products in Ukraine by 24% compared to the same period in 2020, to EUR 6.313 million.
According to the company’s materials, the improvement of this indicator has been facilitated by the introduction of a new marketing model in Ukraine since the end of 2020.
In general, over the six months of 2021, the group’s sales reached EUR 66.671 million, which is almost the same as the level of sales for the same period in 2020.
The largest markets for Olainfarm Group were Latvia (30%), Russia (about 27%), Belarus (about 12%), and Ukraine (over 9%).
Olainfarm is the largest pharmaceutical company in Latvia and one of the largest pharmaceutical companies in the Baltic States. Its product portfolio includes over 60 finished dosage forms, 25 active pharmaceutical ingredients and over 20 chemical intermediates.
Subsidiaries are located in Ukraine, Lithuania, Turkey and Kyrgyzstan, and representative offices – in the Russian Federation, Belarus, Tajikistan, Albania, Mongolia, and Uzbekistan.
